Filing Flows › Alnylam Pharmaceuticals (ALNY) › Next earnings date
Alnylam Pharmaceuticals (ALNY) earnings: beat the estimate
Alnylam Pharmaceuticals (ALNY) reported on Oct 29, 2026 and beat the EPS estimate: $16.26 against $2.25 (+623.0%). Revenue was $1.5B for Q3 2026, +17% year over year. It beat the EPS estimate in 60% of the quarters on record.
The last report
Alnylam Pharmaceuticals reported revenue of $1.5B for the third quarter 2026 (+17% Y/Y), net earnings $2.2B: Net product revenues $1.3B, Total Rare $142M, ONPATTRO $19.6M. How it makes money → · Every quarter →
Alnylam Pharmaceuticals' latest quarter
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
Did Alnylam Pharmaceuticals beat earnings?
Alnylam Pharmaceuticals (ALNY) reported on Oct 29, 2026 and beat the EPS estimate: $16.26 against $2.25 (+623.0%).
When does ALNY report earnings?
The next date is not set yet.
Does Alnylam Pharmaceuticals usually beat earnings?
It beat the consensus EPS estimate in 60% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.